TCT 2023 | SWEDEHEART, Evolution at 5 Years

This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR.

TCT 2023 | SWEDEHEART, evolución  a 5 años

Population characteristics were similar, except that the iFR group had more women, with more diabetes, MI, stroke and chronic obstructive pulmonary disease (COPD).

Primary end point was a composite of all cause death, MI and unplanned revascularization.

At 5 years, there were no significant differences in primary end point, or individual events, which include all cause death, MI and unplanned revascularization. Also, MACE were analyzed in treated and deferred patients, with no differences neither in MACE nor in individual events. 

At group sub-analyzis, no differences were found either, between FFR and iFR patients. 

Read also: TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up.

In conclusion, the authors determined that, at 5 years, there were no significant differences in MACE or in the events of all cause death, MI and unplanned revascularization. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Presented by Matthias Götberg during TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....